Author

E. Costanza

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 1 Biophysics· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:deep learning· 2 Research Focus:drug response / drug discovery· 2 Organism:human· 1 Approach:statistical model· 1 Assay:structural biology· 1 Organism:virus· 1

Frequent Co-Authors

A. Hanke· 1 shared A. R. Beccari· 1 shared A. Thapa· 1 shared A. Zaliani· 1 shared B. P. Joseph· 1 shared B. Uricoli· 1 shared C. Bergh· 1 shared C. Manelfi· 1 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperBiophysics

A. Hanke

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Constitutively synergistic multiagent drug formulations targeting MERTK, FLT3, and BCL-2 for treatment of AML

J. M. Kelvin, J. Jain, A. Thapa, M. Qui, L. A. Birnbaum, S. G. Moore, H. Zecca, R. J. Summers, E. Costanza, B. Uricoli, X. Wang, N. T. Jui, H. Fu, Y. Du, D. DeRyckere, , E. C. Dreaden

The paper develops a nanoscale combination drug formulation targeting MERTK, FLT3, and BCL-2 to treat AML, showing improved synergistic responses in vitro and in patient samples.

bioRxiv · Mar 13, 2023 · PreprintBioengineering

A blueprint for high affinity SARS-CoV-2 Mpro inhibitors from activity-based compound library screening guided by analysis of protein dynamics

J. Gossen, S. Albani, A. Hanke, B. P. Joseph, C. Bergh, M. Kuzikov, E. Costanza, C. Manelfi, P. Storici, P. Gribbon, A. R. Beccari, C. Talarico, F. Spyrakis, E. Lindahl, A. Zaliani, , G. Rossetti

The paper identifies a blueprint for high affinity SARS-CoV-2 Mpro inhibitors by analyzing protein dynamics and redefining druggability through virtual screening and pharmacophore modeling.

bioRxiv · Dec 14, 2020Biophysics